Last reviewed · How we verify
ABT-806
At a glance
| Generic name | ABT-806 |
|---|---|
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- 111In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen (PHASE1)
- PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression (PHASE2)
- A Study of ABT-806 in Subjects With Advanced Solid Tumor Types (PHASE1)
- The Research on 89Zr-ABT806 PET Imaging in High Grade Glioma (NA)
- An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors (PHASE1)
- An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-806 CI brief — competitive landscape report
- ABT-806 updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI